Matteo Cassandri
Overview
Explore the profile of Matteo Cassandri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
504
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gerini G, Traversa A, Cece F, Cassandri M, Pontecorvi P, Camero S, et al.
Cells
. 2025 Jan;
14(2).
PMID: 39851564
Adipose-derived mesenchymal stem cells (ASCs) are commonly employed in clinical treatment for various diseases due to their ability to differentiate into multi-lineage and anti-inflammatory/immunomodulatory properties. Preclinical studies support their use...
2.
Codenotti S, Asperti M, Poli M, Lorenzi L, Pietrantoni A, Cassandri M, et al.
Mol Metab
. 2024 Dec;
92:102085.
PMID: 39706565
Objective: The aim of the present study was to investigate the effects of targeting the mevalonate pathway (MVP) in rhabdomyosarcoma (RMS), a soft tissue tumor with a prevalence in young...
3.
Pezzella M, Quintarelli C, Quadraccia M, Sarcinelli A, Manni S, Iaffaldano L, et al.
J Hematol Oncol
. 2024 Dec;
17(1):127.
PMID: 39695851
Sarcomas are rare, mesenchymal tumors, representing about 10-15% of all childhood cancers. GD2 is a suitable target for chimeric antigen receptor (CAR) T-cell therapy due to its overexpression in several...
4.
Cassandri M, Porrazzo A, Pomella S, Noce B, Zwergel C, Aiello F, et al.
Cell Death Discov
. 2024 Aug;
10(1):351.
PMID: 39107280
Radiotherapy (RT) plays a critical role in the management of rhabdomyosarcoma (RMS), the prevalent soft tissue sarcoma in childhood. The high risk PAX3-FOXO1 fusion-positive subtype (FP-RMS) is often resistant to...
5.
Camero S, Milazzo L, Vulcano F, Ceccarelli F, Pontecorvi P, Pedini F, et al.
BMC Cancer
. 2024 Jul;
24(1):814.
PMID: 38977944
Background: Despite a multimodal approach including surgery, chemo- and radiotherapy, the 5-year event-free survival rate for rhabdomyosarcoma (RMS), the most common soft tissue sarcoma in childhood, remains very poor for...
6.
Codenotti S, Sandrini L, Mandracchia D, Lorenzi L, Corsetti G, Poli M, et al.
Cancers (Basel)
. 2024 Mar;
16(5).
PMID: 38473215
Identifying the molecular mechanisms underlying radioresistance is a priority for the treatment of RMS, a myogenic tumor accounting for approximately 50% of all pediatric soft tissue sarcomas. We found that...
7.
Pomella S, Cassandri M, DArchivio L, Porrazzo A, Cossetti C, Phelps D, et al.
Nat Commun
. 2023 Dec;
14(1):8373.
PMID: 38102140
Rhabdomyosarcomas (RMS) are pediatric mesenchymal-derived malignancies encompassing PAX3/7-FOXO1 Fusion Positive (FP)-RMS, and Fusion Negative (FN)-RMS with frequent RAS pathway mutations. RMS express the master myogenic transcription factor MYOD that, whilst...
8.
Porrazzo A, Cassandri M, DAlessandro A, Morciano P, Rota R, Marampon F, et al.
Cell Oncol (Dordr)
. 2023 Dec;
47(3):717-732.
PMID: 38095764
Background: Radiation therapy (RT) is a key anti-cancer treatment that involves using ionizing radiation to kill tumor cells. However, this therapy can lead to short- and long-term adverse effects due...
9.
Butera A, Agostini M, Cassandri M, De Nicola F, Fanciulli M, DAmbrosio L, et al.
Sci Adv
. 2023 Apr;
9(17):eadg5423.
PMID: 37115925
An essential function of the epidermis is to provide a physical barrier that prevents the loss of water. Essential mediators of this barrier function include ceramides, cholesterol, and very long...
10.
Pomella S, Cassandri M, Melaiu O, Marampon F, Gargari M, Campanella V, et al.
Int J Mol Sci
. 2023 Feb;
24(3).
PMID: 36768994
Oral squamous cell carcinoma (OSCC) is a rapidly progressive cancer that often develops resistance against DNA damage inducers, such as radiotherapy and chemotherapy, which are still the standard of care...